Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Align Technology Inc. pages available for free this week:
- Statement of Comprehensive Income
- Cash Flow Statement
- Analysis of Solvency Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Align Technology Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Gross Profit Margin
- The gross profit margin showed a relatively stable trend from March 2019 through December 2021, maintaining values in the low to mid-70s percentage range. Starting in March 2022, a gradual decline began, with the margin decreasing from approximately 73.62% to around 69.74% by September 2023, indicating some erosion in profitability at the gross level over the most recent periods.
- Operating Profit Margin
- The operating profit margin exhibited fluctuations throughout the observed periods. From early 2019 to the end of 2019, margins hovered around the low 20% range. A notable dip occurred in 2020, with margins falling to a low near 12.74% before recovering steadily to reach a peak above 25% by late 2021. However, after this peak, a steady decline resumed, with margins dropping to approximately 15.35% by September 2023. This suggests operational challenges or increased costs affecting operating efficiency in recent times.
- Net Profit Margin
- The net profit margin presented substantial volatility over the periods. After maintaining levels around 18-20% in 2019, a very sharp and temporary spike occurred in 2020, with margins exceeding 70%, peaking close to 79%. This spike is likely due to one-off factors or accounting adjustments. Following this, margins normalized back to more typical values in the high teens and then gradually decreased to below 10% by late 2023. This downward trend hints at increasing expenses or decreasing revenue quality impacting net profitability.
- Return on Equity (ROE)
- The ROE followed a pattern resembling the net profit margin's trajectory. It remained near 30-33% throughout 2019 before increasing sharply during 2020 to levels above 50%, peaking around 66%. Subsequently, it declined markedly, with values dropping into the single digits by mid-2023. This sharp rise and fall pattern suggests significant changes in equity returns, possibly linked to extraordinary gains or losses during 2020, followed by a return to lower profitability through the equity base.
- Return on Assets (ROA)
- The ROA trend was generally consistent with other profitability metrics. It stayed near 17-19% in 2019, surged significantly in 2020 to levels above 35%, and then declined steadily to near 5.7% by the third quarter of 2023. This trend indicates a declining efficiency in asset utilization to generate profits in recent periods.
Return on Sales
Return on Investment
Gross Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Gross profit margin = 100
× (Gross profitQ3 2023
+ Gross profitQ2 2023
+ Gross profitQ1 2023
+ Gross profitQ4 2022)
÷ (Net revenuesQ3 2023
+ Net revenuesQ2 2023
+ Net revenuesQ1 2023
+ Net revenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several key trends regarding the company's quarterly performance over the analyzed periods.
- Net Revenues
- There is a general upward trajectory in net revenues from March 31, 2018, to December 31, 2021, indicating consistent growth over these years. The figures increased from approximately $437 million to over $1 billion in quarterly revenues during this period. However, starting in early 2022, net revenues exhibit a slight decline and some volatility, fluctuating around the $900 million to $1 billion range and showing no clear increasing trend through September 30, 2023.
- Gross Profit
- Gross profit follows a somewhat similar trend to net revenues with steady growth from 2018 through 2021, rising from about $327 million in Q1 2018 to nearly $760 million by Q2 2021. After peaking in mid-2021, gross profit trends downward throughout 2022, falling to near $617 million by March and June 2023, before showing a slight recovery in the subsequent quarters, ending around $663 million in September 2023.
- Gross Profit Margin
- The gross profit margin remains relatively stable across the periods, generally hovering between the low 70% range and mid-74%. Early data from 2019 show margins around 72% to 74%, with some marginal fluctuations quarter to quarter. The margin peaks at around 74.58% in Q3 2021 but generally trends slightly downward afterward, falling closer to about 69.7% by Q3 2023. This indicates some compression in profitability related to cost of goods sold relative to sales.
In summary, the company experienced significant growth in both net revenues and gross profit through 2021, reflecting successful expansion or increased sales volumes. The gross profit margin was relatively high and stable, suggesting effective cost management during this growth phase. Starting in 2022, however, both revenues and gross profit showed signs of plateauing or mild decline, accompanied by a modest reduction in gross profit margin, indicating increased cost pressures or pricing challenges. The latest quarters suggest a slight recovery in gross profit, but the margin remains below earlier peak levels, warranting monitoring of future trends.
Operating Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Income (loss) from operations | ||||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ3 2023
+ Income (loss) from operationsQ2 2023
+ Income (loss) from operationsQ1 2023
+ Income (loss) from operationsQ4 2022)
÷ (Net revenuesQ3 2023
+ Net revenuesQ2 2023
+ Net revenuesQ1 2023
+ Net revenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several key trends and fluctuations in operational income, net revenues, and operating profit margins over the series of quarterly periods analyzed.
- Income from Operations
- There is a noticeable volatility in income from operations throughout the timeline. Initial quarters show a steady increase from approximately 98 million US dollars in early 2018 to peaks above 176 million US dollars by mid-2019. However, a sharp decline occurs in the second quarter of 2020, where income turns negative, indicating operational losses during that period. Subsequently, income from operations recovers robustly to reach new highs around 268 million US dollars by mid-2021. Post this peak, a downward trend is visible, with income decreasing gradually but remaining positive towards the end of 2023, settling around 166 million US dollars in the last recorded quarter.
- Net Revenues
- Net revenues exhibit a general upward trajectory from 2018 through 2021, starting near 437 million US dollars and rising steadily to slightly above 1 billion US dollars in late 2021. During the mid-2020 period, net revenues dip sharply to approximately 352 million US dollars, coinciding with the operational losses noted, likely reflecting external market pressures or operational disruptions. Post this dip, revenues experience a strong recovery, surpassing pre-dip levels by late 2020 and continuing to grow moderately with minor fluctuations. The revenue trend stabilizes around the 900 million to 1 billion US dollar range through 2022 and into 2023, with some quarters showing slight decreases.
- Operating Profit Margin
- Operating profit margin data is partially available and shows a considerable variation, ranging from approximately 12.7% to above 25%. Margins dip to the lower end during the mid-2020 period in line with the operational income downturn, reflecting decreased efficiency or increased costs during that period. Margins peak above 25% in the first half of 2021, suggesting improved profitability and cost management. Following this peak, a gradual decline in margins occurs, descending close to 15%-16% in the latest quarters. This decline indicates either rising costs relative to revenue or competitive pressures impacting pricing and profitability.
Overall, the data portrays a business experiencing growth and strong performance through 2018 and 2019, facing a significant operational and revenue shock in early 2020, followed by a strong recovery and peak performance in 2021. Since the peak, there is evidence of a moderate decline in profitability margins and operating income, indicating challenges in maintaining earlier growth momentum or increased cost pressures in recent quarters. Revenues remain relatively robust despite these challenges, suggesting sustained demand or market presence.
Net Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ (Net revenuesQ3 2023
+ Net revenuesQ2 2023
+ Net revenuesQ1 2023
+ Net revenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income (Loss) Trend
- The net income exhibited fluctuations over the periods analyzed. Initial quarters from 2018 to early 2019 show values ranging approximately between $71.8 million and $147.1 million, signifying moderate profitability with some variability. Notably, in the first quarter of 2020, there was a substantial spike to over $1.5 billion, which is an outlier compared to all other quarters. This was followed by a sharp decline to a net loss of approximately $40.6 million in the second quarter of 2020. Subsequently, net income stabilized, consistently ranging between $130 million and $200 million through 2021. From early 2022 onward, net income demonstrated a downward trend, reducing to as low as approximately $41.7 million in the first quarter of 2023, before experiencing a moderate recovery in the two subsequent quarters.
- Net Revenues Analysis
- Net revenues show an overall increasing trend from 2018 through 2021. Starting at around $437 million in the first quarter of 2018, revenues rose steadily to surpass $1 billion in several quarters during 2021, indicating significant growth in sales or service income. However, during 2022, revenues appear to have declined gradually, descending from just under $974 million in the first quarter to around $890 million in the third quarter. A mild recovery is seen at the end of 2022 and into 2023, with revenues ranging around $943 million to just over $1 billion, yet remaining below the peak values observed in 2021.
- Net Profit Margin Insights
- The net profit margin presents notable variability. Early values are not reported, but from late 2018 onward, margins mostly range between 15% and 20%, indicating healthy profitability relative to revenue. The exceptional net income in the first quarter of 2020 coincides with an abnormally high profit margin exceeding 70%, which is substantially higher than all other periods, suggesting an extraordinary event influencing profitability. After this period, margins returned to more typical levels in the high teens and mid-teens percentage. From mid-2022 to early 2023, margins compressed significantly, declining to single-digit percentages around 8-9%, parallel to the observed decline in net income and revenues. This suggests decreasing efficiency or increased costs impacting profitability during this timeframe.
- Overall Observations
- The data reflects a company experiencing steady growth in revenues and net income from 2018 through 2021, with a pronounced but singular surge in net income in early 2020. Following this, both net income and profit margins experienced a significant contraction in mid-2020, aligning with evident operational or market challenges. The subsequent stabilization and growth indicate recovery. However, recent periods from 2022 onwards show a downward trajectory in profitability and revenues, implying emerging pressures on financial performance that warrant further investigation to understand underlying causes, such as market conditions or cost dynamics.
Return on Equity (ROE)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||||
Stockholders’ equity | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- Net income demonstrates significant volatility over the observed periods. Initially, from March 2018 to December 2019, it fluctuated in a relatively consistent range between approximately 71,848 and 147,142 thousand US dollars. However, in March 2020, there is an extraordinary jump to over 1.5 million US dollars, which sharply reverses in the following quarter with a loss of 40,602 thousand US dollars. After this, net income recovers and stabilizes around the 150,000 to 200,000 thousand US dollars range through 2021. Starting in 2022, net income declines steadily, reaching a low of 41,775 thousand US dollars in the first quarter of 2023 before showing a modest recovery in subsequent quarters to around 121,427 thousand US dollars by September 2023.
- Stockholders’ Equity
- The stockholders’ equity displays a gradual and consistent increase over the timeframe. Starting at approximately 1.13 billion US dollars as of March 2018, it rises moderately to around 1.35 billion by December 2019. A notable surge occurs in March 2020 when equity more than doubles to approximately 2.85 billion US dollars, maintaining steady growth thereafter. The most recent data points indicate equity levels approaching 3.8 billion US dollars by September 2023, reflecting an overall strengthening of the company's financial base.
- Return on Equity (ROE)
- ROE values are not reported until March 2019. From that point, ROE remains strong, consistently above 29% through December 2019 and then reaching a peak of 66.21% in March 2020, corresponding with the abnormally high net income reported that quarter. Subsequent quarters show a decline in ROE, descending to the mid-50% range in 2020 and dropping further throughout 2021 and 2022. By September 2023, ROE falls to single digits, around 9.54%, indicating a marked reduction in profitability relative to equity, aligning with the observed decrease in net income.
- Overall Trends and Insights
- The financial data reveals a period of steady growth in equity alongside fluctuating profitability. The spike in both net income and ROE in early 2020 is an outlier event, after which profitability metrics normalize but trend downward from 2021 onward. Despite declining ROE and net income from 2022 forward, stockholders’ equity continues to increase, suggesting retained earnings and/or capital injections that strengthen the balance sheet. The declining profitability ratios warrant further investigation into operational efficiency, market conditions, or other factors affecting earnings performance in recent periods.
Return on Assets (ROA)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- The net income exhibits significant volatility over the observed periods. Initially, from early 2018 through 2019, the net income ranges approximately between 70,000 and 147,000 thousand US dollars, showing fluctuations without a clear upward or downward trend. A marked increase is observed in the first quarter of 2020, with net income reaching over 1.5 million thousand US dollars, denoting an exceptional event or an extraordinary gain during this period. Following this peak, the net income sharply declines to a loss of around 40,600 thousand US dollars in the second quarter of 2020, indicative of a substantial adverse impact. Subsequently, net income recovers from the third quarter of 2020 onward, fluctuating between roughly 110,000 and 200,000 thousand US dollars, but without returning to the exceptional level noted earlier in 2020. In 2022 and 2023, the net income shows a declining trend through much of the year, reaching a low point near 41,775 thousand US dollars in early 2023 before rising modestly again towards the third quarter of 2023.
- Total Assets
- Total assets show a generally upward trajectory across the period observed. From early 2018 through late 2019, total assets increase steadily from approximately 1.78 billion to 2.5 billion US dollars. Starting in early 2020, the total assets experience a substantial jump, nearly doubling from around 2.5 billion to approximately 4 billion US dollars by the first quarter of 2020. Following this increase, the total assets continue to grow steadily over subsequent quarters, reaching just over 6.3 billion US dollars by the third quarter of 2023. There is a minor fluctuation around mid-2022 with a slight decrease, but the overall trend remains positive.
- Return on Assets (ROA)
- The return on assets fluctuates notably during certain intervals. Data prior to 2019 is unavailable. Starting in March 2019, ROA is strong, approaching 19.5%, but it declines gradually over the following quarters, dipping to approximately 8% by the beginning of 2021. During 2020, ROA spikes dramatically, peaking above 47%, which coincides with the extraordinary net income observed in the same period. Post-2020, ROA undergoes a consistent downward trend, falling from 36.77% in the last quarter of 2020 to lower single-digit percentages, around 5% to 6%, in 2023. This decline in ROA in the later periods signals a reduction in asset efficiency or profitability relative to the asset base.
- Overall Analysis
- The financial data portrays a company experiencing periods of both substantial growth and significant volatility. The net income and ROA figures highlight extraordinary performance in early 2020, with a sharp spike followed by a swift reversal to loss, suggesting the presence of one-time events or market disruptions. Despite these fluctuations, total assets have increased consistently over the years, indicating ongoing investments or growth initiatives. However, the declining ROA in recent periods raises questions about the efficiency with which the assets are generating earnings. Recent declines in net income and return on assets might warrant further investigation into operational performance, market conditions, or other external factors impacting profitability.